2018 American Transplant Congress
Qualitative Analysis of Facebook Posts Created via the Donor Application
The Donor App is a smartphone app that helps transplant candidates create a Facebook (FB) post telling their story about organ failure and their need…2018 American Transplant Congress
Pancreas Retransplantation: Outcomes of This Technical and Immunological Challenge over 38 Patients
IntroductionPancreas transplantation is now a mastered technique for patients suffering from severe diabetes. However, a significant number of grafts are lost for technical and immunological…2018 American Transplant Congress
BETA-2 Score is an Excellent Tool for Monitoring of Islet Allograft Function and Early Detection of Transplant Dysfunction
1Surgery, University of Chicago, Chicago; 2Nephrology, Medical University of Gdańsk, Gdańsk, Poland.
After validation of BETA-2 scores in our cohort of patients in relation to standard stimulation tests, we decided to assess the practical utility of BETA-2…2018 American Transplant Congress
Hospitality Houses and Transplant Patients: Assessing the Impact of a Hospitality House Dedicated to Transplant Patients and Their Families
Hospitality houses exclusively for transplant patients and their families are a relatively new concept and their connection to medical outcomes is untested. One hospitality house…2018 American Transplant Congress
Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
Department of Pharmacy, The University of Alabama at Birmingham, Birmingham, AL.
Background: Two lymphocyte depleting agents are currently available for renal transplant induction: alemtuzumab (C1H) and rabbit anti-thymocyte globulin (rATG). Studies comparing long-term outcomes between C1H…2018 American Transplant Congress
Long-Term Efficacy and Safety of Prolonged-Release Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate-Release Tacrolimus
Study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) in stable solid organ allograft recipients (aged 5–16 yrs) who participated in a multicenter, Phase II pharmacokinetics…2018 American Transplant Congress
Immunoglobulin Replacement Therapy in Pediatric Renal Transplant Patients
University of Iowa Hospitals and Clinics, Iowa City, IA.
Immunoglobulin replacement therapy decreases infection frequency in patients with primary immunodeficiency; however, there is limited data regarding the use of intravenous immunoglobulin (IVIG) or subcutaneous…2018 American Transplant Congress
Efficacy and Safety of Immediate- and Prolonged-Release Tacrolimus in De Novo Pediatric Transplantation: Randomized Study
This study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) vs immediate-release tacrolimus (IR-T) in de novo pediatric transplant pts. Phase II, parallel-group, multicenter, open-label study…2018 American Transplant Congress
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…2018 American Transplant Congress
Immunogenic HLA Mismatches and Evidence That Belatacept May Be the First Therapy Able to Prevent DQ De Novo DSA: An Analysis of the BENEFIT and BENEFIT-EXT Trial Cohorts
The use of belatacept over cyclosporine is associated with lower rates of DSA development in adult kidney transplantation. However, the effect of belatacept on the…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 14
- Next Page »